ESPR vs OKTA · rev $332.3M vs P/E 84, rev $1.57B
Esperion Therapeutics Inc (ESPR) versus Okta Inc (OKTA) — a side-by-side from cached financials, not a winner call.
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Okta Inc (OKTA) is a software - infrastructure company listed on NASDAQ.
Latest reported ESPR revenue for 2024-12-31 was $332.3M. Net income was -$51.7M. Revenue was up 185.7% from 2023-12-31 to 2024-12-31. ESPR currently screens at market cap $816.9M.
Latest reported OKTA revenue for 2026-07-31 was $1.57B. Net income was $190.0M. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
ESPR currently screens at market cap $816.9M. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
Not investment advice. Open the ESPR and OKTA stock pages for the full models.
Not investment advice.